Show simple item record

dc.contributor.authorConway, JA
dc.contributor.authorKramer, E
dc.date.accessioned2021-08-16T10:32:49Z
dc.date.issued2021-12-10
dc.identifier.issn1876-7958
dc.identifier.issn1876-7958
dc.identifier.urihttp://hdl.handle.net/10026.1/17596
dc.description.abstract

The neurotrophic signaling of glial cell line-derived neurotrophic factor (GDNF) with its canonical receptor, the receptor tyrosine kinase RET, coupled together with the GDNF family receptor alpha 1 is important for dopaminergic neuron survival and physiology in cell culture experiments and animal models. This prompted the idea to try GDNF/RET signaling as a therapeutic approach to treat Parkinson's disease with the hallmark of dopaminergic cell death in the substantia nigra of the midbrain. Despite several clinical trials with GDNF in Parkinson's disease patients, which mainly focused on optimizing the GDNF delivery technique, benefits were only seen in a few patients. In general, the endpoints did not show significant improvements. This suggests that it will be helpful to learn more about the basic biology of this fascinating but complicated GDNF/RET signaling system in the dopaminergic midbrain and about recent developments in the field to facilitate its use in the clinic. Here we will refer to the latest publications and point out important open questions in the field.

dc.format.extent1462-1467
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherMedknow Publications
dc.subjectalpha-synuclein
dc.subjectclinical trials
dc.subjectdopaminergic neurons
dc.subjectglial cell line-derived neurotrophic factor
dc.subjectGFR alpha 1
dc.subjectgut-brain axis
dc.subjectNedd4
dc.subjectParkin
dc.subjectParkinson's disease
dc.subjectRET
dc.titleIs activation of GDNF/RET signaling the answer for successful treatment of Parkinson’s disease? A discussion of data from the culture dish to the clinic
dc.typejournal-article
dc.typeReview
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34916419
plymouth.issue7
plymouth.volume17
plymouth.publication-statusPublished
plymouth.journalNeural Regeneration Research
dc.identifier.doi10.4103/1673-5374.327330
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/Faculty of Science and Engineering
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeIndia
dcterms.dateAccepted2021-07-12
dc.rights.embargodate2021-12-14
dc.identifier.eissn1876-7958
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.4103/1673-5374.327330
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-12-10
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV